Ezetimibe Tablets, USP 10mg (Camber, USA)
APO-EZETIMIBE ezetimibe 10mg tablet blister pack - ARTG 263212
BTC Ezetimibe 10mg tablet blister pack - ARTG 391682
EZEMICHOL ezetimibe 10mg tablet blister pack - ARTG 263224
Ezetimibe Sandoz ezetimibe 10mg tablet blister pack - ARTG 263045
EZETROL ezetimibe 10mg tablet blister pack - ARTG 91161
PHARMACOR EZETIMIBE ezetimibe 10 mg tablet blister pack - ARTG 276975
PHARMACOR EZETIMIBE ezetimibe 10 mg tablet bottle pack - ARTG 276974
Ezetimibe administered alone, or with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.
Ezetimibe, administered with a statin, is indicated for patients with Homozygous Familial Hypercholesterolaemia (HoFH). Patients may also receive adjunctive treatments (e.g., LDL apheresis).
Ezetimibe is indicated for the reduction of elevated sitosterol and campesterol levels in patients with Homozygous Familial Sitosterolaemia (Phytosterolaemia).
Ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with Heterozygous Familial Hypercholesterolaemia (HeFH) where use of a combination product is appropriate:
- Patients not appropriately controlled with a statin or ezetimibe alone
- Patients already treated with a statin and ezetimibe
Ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated in adolescent patients (10-17 years old) with Homozygous Familial Hypercholesterolaemia (HoFH). Patients may also receive adjunctive treatments (e.g. LDL apheresis).
